Qualitas buys genomics specialist Imegen

As part of the deal, Qualitas injected fresh capital from its Q-Growth fund, alongside biotech-focused consultancy firm Biolty, according to press reports. Furthermore, the company’s CEO, Angela Perez, will retain a minority stake and will continue to lead the business.

The investor syndicate acquired its controlling stake from Realiza Business Angels and aims to expand the business internationally following the transaction.

Qualitas currently manages two vehicles: fund-of-funds Qualitas Mutual Private Equity Fund I, which raised €60m and targets the European mid-market private equity market; and 2014-vintage growth capital fund Q-Growth, which also manages a €60m pot and targets companies with revenues in the €3-15m bracket.

Company
Imegen is headquartered in Valencia and specialises in genetic diagnosis and genomics research. The company was established in 2009 and currently employs a staff of 60.

According to press reports, the company posted a turnover of €4.1m in 2015.

People
Qualitas Equity Partners – Borja Oyarzábal (partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• Healthcare
• Southern Europe
• Venture
• Spain